Neurocrine Biosciences | NBIX - Market Capitalization


Neurocrine Biosciences reported $13.1B in Market Capitalization this April of 2026, considering the latest stock price and the number of outstanding shares.





Market Capitalization Change Date
AbbVie USD 403.83B 5.2B Dec/2025
Acadia Pharmaceuticals USD 4.52B 919M Dec/2025
Agios Pharmaceuticals USD 1.59B 745M Dec/2025
ALKERMES USD 4.62B 333M Dec/2025
Alnylam Pharmaceuticals USD 52.54B 7.24B Dec/2025
Amgen USD 176.25B 24.32B Dec/2025
Biogen USD 25.82B 5.28B Dec/2025
BioMarin Pharmaceutical USD 11.42B 1.02B Dec/2025
Cytokinetics USD 7.77B 1.19B Dec/2025
Enanta Pharmaceuticals USD 122M 98M Dec/2024
Exelixis USD 11.75B 959M Dec/2025
Gilead Sciences USD 152.28B 14.55B Dec/2025
Halozyme Therapeutics USD 7.91B 664M Dec/2025
Incyte USD 19.39B 2.83B Dec/2025
Ionis Pharmaceuticals USD 12.81B 2.39B Dec/2025
Nektar Therapeutics USD 14.34B 13.48B Apr/2026
Neurocrine Biosciences USD 14.14B 218M Dec/2025
Pfizer USD 141.57B 6.48B Dec/2025
Prothena USD 514M 11M Dec/2025
Regeneron Pharmaceuticals USD 81.12B 21.53B Dec/2025
Repligen USD 9.22B 1.7B Dec/2025
Sarepta Therapeutics USD 2.26B 238M Dec/2025
Teva Pharmaceutical Industries USD 36.42B 14.06B Dec/2025
Ultragenyx Pharmaceutical USD 2.22B 680M Dec/2025
Vertex Pharmaceuticals USD 115.03B 14.61B Dec/2025